The thesis

TG Therapeutics has transformed from a development-stage bet into a commercial-stage biopharmaceutical with reported revenue growth of 641% year over year, driven by the commercial ramp of its MS drug Briumvi. Gross margins of 8,304% and a net margin of 6,595% reflect the economics of a royalty-like drug launch with minimal cost of goods — the numbers look extraordinary because they are, for now. The analyst consensus is firmly bullish and the P/E sits at just 16.6x, which appears cheap against those growth figures. But the DCF intrinsic value is deeply negative at negative 63 dollars, signaling that discounted future cash flows do not support the current price — the tension between the trailing growth story and the forward cash generation picture is the central risk the consensus is glossing over.

Why now

The market is in active risk-off rotation triggered by geopolitical escalation — U.S. strikes on Iran have pushed the Nasdaq and S&P down over 1% with the Dow shedding 600 points, creating an environment where high-multiple growth names get repriced fast even when earnings look clean. TGTX's composite conviction score of 49 out of 100 sits squarely in the middle — not a name institutions are rushing to defend in a flight-to-safety tape.

What to watch

Watch Briumvi net revenue in each of the next two quarterly earnings prints — any sequential deceleration below 15% quarter over quarter would signal the launch peak is in and force a rerating. Monitor gross-to-net discount trends and any payer coverage decisions, as formulary positioning changes are the earliest indicator of whether the unit economics hold at scale.

Key risks

The negative DCF value is the loudest warning: if Briumvi's revenue growth decelerates as the initial launch bolus normalizes, the multiple on current earnings loses its justification quickly. Competitive pressure in the anti-CD20 MS space from established players like Roche and Novartis could compress pricing and limit market share gains before the cash flow profile matures. The current macro environment adds a timing risk — geopolitical shocks historically accelerate rotation out of mid-cap biotech regardless of company-specific fundamentals.